Prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitus

Background: Evidence in the literature indicates that patients with type 2 diabetes  (T2D) have a very low level of adherence to pharmacological treatment and that despite several interventions to improve it, a number of obstacles to optimal care limit the extent to which such goals can be achieved....

Full description

Bibliographic Details
Main Authors: Camila Vicenzi, Milene Moehlecke
Format: Article
Language:English
Published: Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS) 2019-02-01
Series:Clinical and Biomedical Research
Subjects:
Online Access:https://seer.ufrgs.br/hcpa/article/view/82726
id doaj-6557de6a9e904cd982f3fa087a51a784
record_format Article
spelling doaj-6557de6a9e904cd982f3fa087a51a7842020-11-25T00:55:56ZengHospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS)Clinical and Biomedical Research0101-55752357-97302019-02-0138439068Prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitusCamila Vicenzi0Milene Moehlecke1Faculdade de Medicina, Universidade Luterana do Brasil (ULBRA), Canoas, BrasilDepartamento de Medicina Interna, Universidade Luterana do Brasil (ULBRA), Canoas, BrasilBackground: Evidence in the literature indicates that patients with type 2 diabetes  (T2D) have a very low level of adherence to pharmacological treatment and that despite several interventions to improve it, a number of obstacles to optimal care limit the extent to which such goals can be achieved. Aims: To assess the sociodemographic profile of patients with T2D, describing prevalence of adherence to drug treatment among them. Additionally, this study attempts to identify the main reasons for nonadherence. Methods: This cross-sectional study evaluated patients with T2D for at least 6 months who are regularly followed at an endocrinology outpatient clinic or who have been admitted to a university hospital. Adherence was assessed by a modified Morisky-Green test and the Batalla test. Results: Ninety-six patients were included, mostly women (59%), white (76%), and with mean age of 52 ± 12 years. Only 49% of patients adhered to drug treatment according to the Batalla test, while 24% were classified as high adherence, 41% as moderate adherence and 34% as low adherence to drug treatment according to the modified Morisky-Green test. Considering glycated hemoglobin levels as a reference method, only 37% of patients were within the currently recommended values, with higher adherence among women compared to men (44% vs. 23%, P = 0.044). Conclusion: The prevalence of adherence among patients with T2D was very low. Older age, insulin therapy and male sex were more strongly associated with worse adherence. The main barrier limiting treatment adherence was lack of motivation, especially due to difficulties in adopting a healthy and balanced diet. Keywords: Type 2 diabetes; adherence; chronic diseasehttps://seer.ufrgs.br/hcpa/article/view/82726Type 2 diabetesadherencechronic disease
collection DOAJ
language English
format Article
sources DOAJ
author Camila Vicenzi
Milene Moehlecke
spellingShingle Camila Vicenzi
Milene Moehlecke
Prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitus
Clinical and Biomedical Research
Type 2 diabetes
adherence
chronic disease
author_facet Camila Vicenzi
Milene Moehlecke
author_sort Camila Vicenzi
title Prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitus
title_short Prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitus
title_full Prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitus
title_fullStr Prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitus
title_full_unstemmed Prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitus
title_sort prevalence of adherence to pharmacological treatment in patients with type 2 diabetes mellitus
publisher Hospital de Clinicas de Porto Alegre ; Universidade Federal do Rio Grande do Sul (UFRGS)
series Clinical and Biomedical Research
issn 0101-5575
2357-9730
publishDate 2019-02-01
description Background: Evidence in the literature indicates that patients with type 2 diabetes  (T2D) have a very low level of adherence to pharmacological treatment and that despite several interventions to improve it, a number of obstacles to optimal care limit the extent to which such goals can be achieved. Aims: To assess the sociodemographic profile of patients with T2D, describing prevalence of adherence to drug treatment among them. Additionally, this study attempts to identify the main reasons for nonadherence. Methods: This cross-sectional study evaluated patients with T2D for at least 6 months who are regularly followed at an endocrinology outpatient clinic or who have been admitted to a university hospital. Adherence was assessed by a modified Morisky-Green test and the Batalla test. Results: Ninety-six patients were included, mostly women (59%), white (76%), and with mean age of 52 ± 12 years. Only 49% of patients adhered to drug treatment according to the Batalla test, while 24% were classified as high adherence, 41% as moderate adherence and 34% as low adherence to drug treatment according to the modified Morisky-Green test. Considering glycated hemoglobin levels as a reference method, only 37% of patients were within the currently recommended values, with higher adherence among women compared to men (44% vs. 23%, P = 0.044). Conclusion: The prevalence of adherence among patients with T2D was very low. Older age, insulin therapy and male sex were more strongly associated with worse adherence. The main barrier limiting treatment adherence was lack of motivation, especially due to difficulties in adopting a healthy and balanced diet. Keywords: Type 2 diabetes; adherence; chronic disease
topic Type 2 diabetes
adherence
chronic disease
url https://seer.ufrgs.br/hcpa/article/view/82726
work_keys_str_mv AT camilavicenzi prevalenceofadherencetopharmacologicaltreatmentinpatientswithtype2diabetesmellitus
AT milenemoehlecke prevalenceofadherencetopharmacologicaltreatmentinpatientswithtype2diabetesmellitus
_version_ 1725228815954739200